NOVEL REPEAT ELEMENTS FOR GENOME ANALYSIS

Information

  • Research Project
  • 2114976
  • ApplicationId
    2114976
  • Core Project Number
    R43CA071315
  • Full Project Number
    1R43CA071315-01
  • Serial Number
    71315
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1995 - 31 years ago
  • Project End Date
    3/31/1996 - 30 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1995 - 31 years ago
  • Budget End Date
    3/31/1996 - 30 years ago
  • Fiscal Year
    1995
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/27/1995 - 31 years ago

NOVEL REPEAT ELEMENTS FOR GENOME ANALYSIS

The goal of this Phase I project is to isolate and characterize new chromosome-specific human repetitive DNA elements. The resulting probes will be valuable for cytogenetic cancer diagnostics. Our preliminary results suggest that random amplification of polymorphic DNA (RAPD) is a valuable approach for the discovery of chromosome-specific and polymorphic repetitive DNA elements. Phase I will involve systematic and high- throughput employment of RAPD in a genome-wide search for such elements. The repetitive DNAs will be cloned, then characterized by sequencing, chromosomal localization and sublocalization, heterozygosity determination, evaluation of evolutionary conservation, and determination of average copy number. Additionally, Phase I will include modeling cytogenetic analysis of cancer-relevant chromosomal aberrations using chromosome-specific repetitive DNA probes. Our model system will employ a novel repetitive element mapping to chromosome 20q12, which we discovered in preliminary research using RAPD, as a FISH probe in interphase nuclei representing specific hematological malignancies known to have chromosomal aberrations in this vicinity. PROPOSED COMMERCIAL APPLICATION: The new human repetitive elements will have a wide range of commercially important uses including probes for cytogenetic cancer diagnosis, genetic mapping, positional cloning, and the identification of individuals. Additionally, highly localized repeats may eventually be valuable reagents in gene therapeutics, since future gene therapy vectors may exploit chromosomal region-specific repeats for targeting DNA into specific sites of the human genome.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    GENAISSANCE PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    NEW HAVEN
  • Organization State
    CT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    06511
  • Organization District
    UNITED STATES